[1] Hankey G. J., Stroke: how large a public health problem, and how can the neurologist help? Arch. Neurol., 1999, 56, 748–754 http://dx.doi.org/10.1001/archneur.56.6.748CrossrefGoogle Scholar

[2] Kim A. S., Johnston S.C., Global variation in the relative burden of stroke and ischemic heart disease, Circulation, 2011, 124, 314–323 http://dx.doi.org/10.1161/CIRCULATIONAHA.111.018820CrossrefGoogle Scholar

[3] Mattson M. P., Shea T. B., Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders, Trends Neurosci., 2003, 26, 137–146 http://dx.doi.org/10.1016/S0166-2236(03)00032-8CrossrefGoogle Scholar

[4] Zou C. G., Banerjee R., Homocysteine and redox signaling, Antioxid. Redox Signal., 2005, 7, 547–559 http://dx.doi.org/10.1089/ars.2005.7.547CrossrefGoogle Scholar

[5] Schroecksnadel K., Frick B., Winkler C., Leblhuber F., Wirleitner B., Fuchs D., Hyperhomocysteinemia and immune activation, Clin. Chem. Lab. Med., 2003, 41, 1438–1443 http://dx.doi.org/10.1515/CCLM.2003.221CrossrefGoogle Scholar

[6] Alfthan G., Pekkanen J., Jauhiainen M., Pitkäniemi J., Karvonen M., Tuomilehto J. et al., Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study, Atherosclerosis, 1994, 106, 9–19 http://dx.doi.org/10.1016/0021-9150(94)90078-7CrossrefGoogle Scholar

[7] Howard V. J., Sides E. G., Newman G. C., Cohen S. N., Howard G., Malinow M. R. et al., Changes in plasma homocyst(e)ine in the acute phase after stroke, Stroke, 2002, 33, 473–478 http://dx.doi.org/10.1161/hs0202.103069CrossrefGoogle Scholar

[8] Karttunen V., Alfthan G., Hiltunen L., Rasi V., Kervinen K., Kesäniemi Y. A. et al., Risk factors for cryptogenic ischaemic stroke, Eur. J. Neurol., 2002, 9, 625–632 http://dx.doi.org/10.1046/j.1468-1331.2002.00464.xCrossrefGoogle Scholar

[9] Kristensen B., Malm J., Nilsson T.K., Hultdin J., Carlberg B., Dahlén G. et al., Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke, Stroke, 1999, 30, 974–980 http://dx.doi.org/10.1161/01.STR.30.5.974CrossrefGoogle Scholar

[10] Lindgren A., Brattström L., Norrving B., Hultberg B., Andersson A., Johansson B.B., Plasma homocysteine in the acute and convalescent phases after stroke, Stroke, 1995, 26, 795–800 http://dx.doi.org/10.1161/01.STR.26.5.795CrossrefGoogle Scholar

[11] Meiklejohn D. J., Vickers M. A., Dijkhuisen R., Greaves M., Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke, Stroke, 2001, 32, 57–62 http://dx.doi.org/10.1161/01.STR.32.1.57CrossrefGoogle Scholar

[12] Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M. et al., Homocysteine lowering with folic acid and B vitamins in vascular disease, N. Engl. J. Med., 2006, 354, 1567–1577 http://dx.doi.org/10.1056/NEJMoa060900CrossrefGoogle Scholar

[13] Bønaa K. H., Njølstad I., Ueland P. M., Schirmer H., Tverdal A., Steigen T. et al., Homocysteine lowering and cardiovascular events after acute myocardial infarction, N. Engl. J. Med., 2006, 354, 1578–1588 http://dx.doi.org/10.1056/NEJMoa055227CrossrefGoogle Scholar

[14] Toole J. F., Malinow M. R., Chambless L. E., Spence J. D., Pettigrew L. C., Howard V. J. et al., Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial, JAMA, 2004, 291, 565–575 http://dx.doi.org/10.1001/jama.291.5.565CrossrefGoogle Scholar

[15] National Institute for Health and Clinical Excellence, Clinical guideline on Stroke: Diagnosis and initial management of acute stroke and transient ischemic attack (TIA), NICE clinical guideline 68, London: National Institute for Health and Clinical Excellence, 2008 Google Scholar

[16] Voortman A., Melse-Boonstra A., Schulz J. M., Burema J., Katan M. B., Verhoef P., Optimal time interval between repeated blood sampling for measurements of total homocysteine in healthy individuals, Clin. Chem., 2001, 47, 1839–1841 Google Scholar

[17] Haapaniemi E., Helenius J., Soinne L., Syrjala M., Kaste M., Tatlisumak T., Serial measurements of plasma homocysteine levels in early and late phases of ischemic stroke, Eur. J. Neurol., 2007, 14, 12–17 http://dx.doi.org/10.1111/j.1468-1331.2006.01518.xCrossrefWeb of ScienceGoogle Scholar

[18] Egerton W., Silberberg J., Crooks R., Ray C., Xie L., Dudman N., Serial measures of plasma homocyst(e)ine after acute myocardial infarction, Am. J. Cardiol., 1996, 77, 759–761 http://dx.doi.org/10.1016/S0002-9149(97)89213-2CrossrefGoogle Scholar

[19] Sastry B. K., Indira N., Anand B., Kedarnath, Prabha B. S., Raju B. S., A case-control study of plasma homocysteine levels in South Indians with and without coronary artery disease, Indian Heart J., 2001, 53, 749–753 Google Scholar

[20] Iqbal M. P., Ishaq M., Kazmi K. A., Yousuf F. A., Mehboobali N., Ali S. A. et al., Role of vitamins B6, B12 and folic acid on hyperhomocysteinemia in a Pakistani population of patients with acute myocardial infarction, Nutr. Metab. Cardiovasc. Dis., 2005, 15, 100–108 http://dx.doi.org/10.1016/j.numecd.2004.05.003CrossrefGoogle Scholar

[21] Iqbal M. P., Fatima T., Parveen S., Yousuf F. A., Shafiq M., Mehboobali N. et al., Lack of association of methylenetetrahyclrofolate reductase 677C>T mutation with coronary artery disease in Pakistani population, J. Mol. Genet. Med., 2005, 1, 26–32 Google Scholar

[22] Holmes M. V., Newcombe P., Hubacek J. A., Sofat R., Ricketts S. L., Cooper J. et al., Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials, Lancet, 2011, 378, 584–594 http://dx.doi.org/10.1016/S0140-6736(11)60872-6Web of ScienceCrossrefGoogle Scholar

[23] Hultdin J., Van Guelpen B., Winkvist A., Hallmans G., Weinehall L., Stegmayr B. et al., Prospective study of first stroke in relation to plasma homocysteine and MTHFR 677C>T and 1298A>C genotypes and haplotypes — evidence for an association with hemorrhagic stroke, Clin. Chem. Lab. Med., 2011, 49, 1555–1562 http://dx.doi.org/10.1515/CCLM.2011.234CrossrefWeb of ScienceGoogle Scholar

[24] Somarajan B. I., Kalita J., Mittal B., Misra U. K., Evaluation of MTHFR C677T polymorphism in ischemic and hemorrhagic stroke patients. A case-control study in a Northern Indian population, J. Neurol. Sci., 2011, 304, 67–70 http://dx.doi.org/10.1016/j.jns.2011.02.010Web of ScienceCrossrefGoogle Scholar

[25] Iso H., Moriyama Y., Sato S., Kitamura A., Tanigawa T., Yamagishi K. et al., Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese, Circulation, 2004, 109, 2766–2772 http://dx.doi.org/10.1161/01.CIR.0000131942.77635.2DCrossrefGoogle Scholar

[26] Li Z., Sun L., Zhang H., Liao Y., Wang D., Zhao B. et al., Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China, Stroke, 2003, 34, 2085–2090 http://dx.doi.org/10.1161/01.STR.0000086753.00555.0DCrossrefGoogle Scholar